This paper explores the economic incentives that oncologists face when deciding between oral and intravenous oncolytics and their impact on prescribing behavior.
Karen E. Van Nuys, PhD
Advertisement
Articles by Karen E. Van Nuys, PhD
Advertisement
Latest Updated Articles
- Practice Economics and the Decision to Prescribe Oral Oncolytics
December 5th 2013
Advertisement
Advertisement
Trending on Pharmacy Times
1
Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma
2
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
3
Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas
4
Are Non-Opioid Therapies Finally Challenging Opioids in Acute Pain Management?
5